For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.
Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.
Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.
Background reading:
For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.
'The Interview': Jelly Roll Cannot Believe How His Life Turned Out
How Air-Conditioning Conquered America
A Controversial Crackdown on Homeless Encampments
How One Tech Monopoly Paved the Way for Another
Harris Takes the Lead in Key States
Inside the Three Worst Weeks of Trump’s Campaign
The Sunday Read: ‘The Woman Who Could Smell Parkinson’s’
'The Interview': James Lankford Tried to Solve Immigration for the GOP
Breaking’s Olympic Debut
Dispatches From a Kamala Harris Field Office
Harris Chooses Walz
What Just Happened on Wall Street?
She Used to Be Friends With JD Vance
The Sunday Read: ‘Online Dating After 50 Can Be Miserable. But It’s Also Liberating.’
'The Interview': Vince Vaughn Turned This Interview Into Self-Help
The Secret Succession Fight That Will Determine the Future of Fox News
The Long Shadow of Julian Assange’s Conviction
An Escalating War in the Middle East
The V.P.’s Search for a V.P.
A Radical Reboot of Nuclear Energy
Create your
podcast in
minutes
It is Free
Up First from NPR
The Ezra Klein Show
Matter of Opinion
Economist Podcasts
The Headlines